Compare Adaptive Biotechnologies Corp (ADPT) vs Under Armour Inc Class A (UA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Under Armour Inc Class A — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Under Armour Inc Class A trades at $6.4 (market cap $2.84B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ADPT | UA | |
|---|---|---|
Market Cap | $3.33B | $2.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $7.88 |
52-Week Low | $10.24 | $3.96 |
Enterprise Value | $3.19B | $4.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Under Armour (UA) trades at $6.64, up 2.47% with a bullish technical signal from moving averages despite bearish oscillators. The company reported mixed Q1 2026 results, missing EPS expectations after beating in previous quarters. Revenue declined to $5.0B in 2026 with a net loss of -$496M, though valuation remains reasonable with P/S of 0.57. Recent news highlights a Dodge collaboration and insider buying by Prem Watsa.
The outlook remains challenging with declining revenue and negative profitability, but analyst consensus leans positive with 40% buy ratings. Key risks include sustained revenue declines and competitive pressures, while potential catalysts include premium product focus and inventory discipline. The stock presents a turnaround opportunity with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
